Cimlanod is a second-generation Nitroxyl (HNO) donor for heart failure with positive lusitropic and inotropic as well as vasodilatory effects. Cimlanod delivers HNO via pH-dependent chemical breakdown when exposed to the neutral pH environment of the bloo
Hemorphin 4 is an endogenous opioid peptide of the hemorphin family which has antinociceptive properties and is derived from the β-chain of hemoglobin in the bloodstream.
DB-766 is a potential chemotherapeutic candidate for Chagas' disease treatment. DB-766 exhibits strong trypanocidal activity and excellent selectivity for bloodstream trypomastigotes and intracellular amastigotes (Y strain), giving IC(50)s of 60 and 25 nM
(2-Pyridyldithio)-PEG1-hydrazine is a one-unit cleavable polyethylene glycol (PEG) linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This linker offers the advantage of controlled release of the drug payload from the ADC construct. It is utilized in the conjugation process between the antibody and the cytotoxic drug, enabling the targeted delivery of the drug to cancer cells. The (2-pyridyldithio) group of this linker provides stability during circulation in the bloodstream, while the hydrazine moiety allows for efficient drug release at the tumor site. Overall, the (2-pyridyldithio)-PEG1-hydrazine linker serves as a valuable tool in the development of targeted chemotherapeutic agents for cancer treatment.
MPEG-2000-DSPE sodium is a phospholipid PEG conjugate with hydrophilicity and hydrophobicity. It is utilized in liposome synthesis to enhance the hydrophilicity of liposomes, thereby prolonging their circulation in the bloodstream. This compound is commonly employed for the investigation of anticancer and antimalarial agents.
The truncated glucagon-like peptides GLP-1(7-37) is naturally occurring peptide product of the preproglucagon gene that are synthesized primarily in the intestine and acts as incretin that are released from the intestine into the bloodstream in response to food and stimulate insulin secretion. GLP-1(7-37) produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in Sprague-Dawley Rats at a dosing rang of 0.5, 5, or 50 pmol min kg. Further, infusion of GLP-1(7-37) for 60 mins produced a small transitory increase in plasma insulin concentration in fasted rats and fed rats and a slight transitory decrease in plasma glucose concentration. Moreover, GLP-1(7-37) (5 pmol min kg IV) infusion for 6 h in Sprague-Dawley rats produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle[1].